Skip Navigation LinksHome > July 2010 - Volume 16 - Issue 7 > Outcome of medical treatment of stricturing and penetrating...
Inflammatory Bowel Diseases:
doi: 10.1002/ibd.21160
Original Clinical Articles: Stricturing and Penetrating CD: Original Article

Outcome of medical treatment of stricturing and penetrating Crohn's disease: A retrospective study

Samimi, Roxana MD1; Flasar, Mark H. MD2,3; Kavic, Stephen MD4; Tracy, Kathleen PhD5; Cross, Raymond K. MD, MS2,3,*

Collapse Box

Abstract

Background:: Outcomes of medical treatment in patients with stricturing and penetrating Crohn's disease (CD) are not well characterized.

Methods:: Adults with stricturing and penetrating CD who underwent medical treatment from 2004 to 2008 were evaluated. We assessed response rates to medical treatment, time to relapse or surgery, and postoperative complications.

Results:: In all, 53 patients underwent medical therapy. 60% had stricturing disease, 11% had penetrating, and 28% had both. Disease location was ileal in 38%, colonic in 2%, and ileocolonic in 60%. At 30, 60, and 90 days, 54%, 60%, and 64% experienced a response to medical therapy, respectively. At 30 days, 75% of patients with ileal CD responded to therapy compared to 38% of patients with ileocolonic CD (P = 0.026). Overall, 64% of patients required surgery. Patients with ileocolonic disease required surgery at 0.55 years versus 1.07 years in patients with ileal disease (P = 0.023). 24% of patients experienced an anastomotic leak, fistula, or abscess (IASC). 29% of patients with penetrating disease developed IASC compared to 6% of patients with stricturing disease (P = 0.047). 32% of patients on biologic therapy had IASC compared to 0% of those not on biologics (P = 0.059).

Conclusions:: The outcomes of medical treatment of stricturing or penetrating CD are poor, as 64% ultimately require surgery. Important factors that seem to be associated with either failed therapy include ileocolonic or colonic disease location. We report a high rate of IASC, especially in patients with penetrating disease and those treated with biologic therapy. This should be considered prior to attempted medical therapy. (Inflamm Bowel Dis 2009)

© Crohn's & Colitis Foundation of America, Inc.

You currently do not have access to this article.

You may need to:

Note: If your society membership provides for full-access to this article, you may need to login on your society’s web site first.

Login

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.